Cryo-Cell amends Duke license, adds milestone for autism MSC therapy; funds IMPACT study

CRYO CELL INTERNATIONAL INC

Second Amendment removes final license fee payment to Duke; license fee now paid in full.
New milestone payment triggered upon FDA approval of first cord tissue MSC product for autism spectrum disorder.
New milestone requires Cryo-Cell to open manufacturing facility for licensed product before Phase III trial initiation.
Cryo-Cell entered Research Agreement to fund Duke IMPACT Study; 14 monthly payments starting April 2023.
IMPACT Study targeted accrual reached: 137 patients; draft publication due no later than September 30, 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CRYO CELL INTERNATIONAL INC entered into Clinical Study and Research Agreement with Duke valued at 14 equal monthly payments commencing in April 2023 and a final payment (effective 2023-03-03).

Action: entry
Agreement: collaboration
Counterparty: Duke
Value: 14 equal monthly payments commencing in April 2023 and a final payment
Effective: 2023-03-03

Exact text from the filing

As part of the Second Amendment, on March 3, 2023, the Company entered into the Clinical Study and Research Agreement (the “Research Agreement”) with Duke to provide funding to complete the Duke IMPACT Study

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CRYO CELL INTERNATIONAL INC amended Second Amendment to the License Agreement with Duke (effective 2023-02-17).

Action: amendment
Agreement: license
Counterparty: Duke
Effective: 2023-02-17

Exact text from the filing

On February 17, 2023, Cryo-Cell International, Inc. ("Company") entered into a Second Amendment to the License Agreement (the “Second Amendment”) with Duke

View on SEC.gov

Browse all material agreements →

CRYO CELL INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0000950170-23-007079

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.